PsychoGenics Announces Positive Phase-IIa For Its First-in-Class Partial 5-HT1A - 5-HT1B Receptor Agonist In ADHD
PsychoGenics Inc. announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company's lead partial 5-HT1A - 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD).
Sciele Pharma Announces That Addrenex Has Completed Enrollment Of Pivotal Phase III Trial For Clonicel For ADHD
Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder (ADHD) in children.
Cutting Edge Acid Reflux Test Patient-Friendly And Accurate, Improving Diagnosis And Treatment - Restech Dx-pH Measurement System Adopted By CCENT
The Restech Corporation announced that the Central California Ear, Nose & Throat Medical Group (CCENT) of Fresno, California, has adopted the Restech Dx-pH Measurement System to detect acid reflux in the throat. An alarming increase in the incidence of gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux disease (LPRD) in Americans has led to the need for accurate diagnosis of acid reflux as provided by this system.
Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.
VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints.
Sensory Treatment Reduces Autistic Mannerisms
Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they're seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.
FDA Approves Strattera R For Maintenance Of ADHD In Children And Adolescents
Eli Lilly and Company (NYSE: LLY) announced that the United States Food and Drug Administration (FDA) has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents.
MGH Study Confirms Benefit Of Surgery For Gastroesophageal Reflux
Despite the growing availability of prescription and over-the-counter medications for gastroesophageal reflux disease (GERD), surgical treatment remains a viable alternative for patients whose symptoms persist. In the May 2008 Archives of Surgery, surgeons from Massachusetts General Hospital (MGH) report their survey of almost 200 patients who had laparoscopic antireflux surgery at the MGH over a 10-year period.
TAK-390MR Phase 3 Data Presented At Digestive Disease Week
TAP Pharmaceutical Products Inc. have reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE.
The Features Of Chinese Patients With Reflux Esophagitis
Gastroesophageal reflux disease (GERD) is described as the chronic symptoms and/or tissue damage caused by the reflux of abnormal gastric contents to the esophagus. GERD is a common disease, with associated typical symptoms of heartburn and regurgitation.